The outcomes of relapsed Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ALL) resistant to new drugs such as tyrosine kinase inhibitors. inotuzumab ozogamicin (InO) and blinatumomab are dismal. We treated two cases of Ph+ALL resistant to these drugs that achieved long-term survival after treatment with chimeric antigen receptor (CAR)-T cell therapy or a second alloge... https://www.roneverhart.com/BULK-PACK-3-12-Ivory-Dragon-Cloud-Premium-Texture-Fibrous-Paper-Lantern/